Whereas, Many people living with serious mental illnesses (for example, bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder) or gastrointestinal disorders (for example, gastroparesis, upset stomach, nausea and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics; and
Whereas, While ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs, and fingers or toes; and
Whereas, Even mild symptoms of TD can impact people physically, socially and emotionally; and
Whereas, It is estimated that TD affects approximately 600,000 people in the United States and approximately 65 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms; and
Whereas, It is important that people taking these medications be monitored for TD by a healthcare provider. Regular screening for TD is recommended by the American Psychiatric Association; and
Whereas, Clinical research has led to approval of treatments for adults with TD by the U.S. Food and Drug Administration. Recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; and
Whereas, Michigan can raise awareness of TD among the public and medical community; now, therefore, be it
Resolved by the House of Representatives, That the members of this legislative body declare May 5-11, 2024, as Tardive Dyskinesia Awareness Week in the state of Michigan. We encourage anyone experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms.
Co-sponsored by Reps.
Adopted in the House by voice vote
